Jump to main content
Jump to site search

Issue 10, 2014
Previous Article Next Article

Non-classical β-carbonic anhydrase inhibitors-towards novel anti-mycobacterials

Author affiliations

Abstract

Mycobacterial carbonic anhydrases, such as the essential protein Rv3588c, are attractive drug targets since they constitute a different class of carbonic anhydrases than those found in humans. A natural product library has been screened for compounds that inhibit mycobacterial carbonic anhydrases but lack the much-exploited sulfonamide/sulfamate group. The identified inhibitors of mycobacterial Rv3588c are likely to affect the enzyme at a site different from the catalytic centre – a concept which may be exploited for novel specific anti-mycobacterials.

Graphical abstract: Non-classical β-carbonic anhydrase inhibitors-towards novel anti-mycobacterials

Back to tab navigation

Supplementary files

Publication details

The article was received on 18 Jul 2014, accepted on 10 Aug 2014 and first published on 12 Aug 2014


Article type: Concise Article
DOI: 10.1039/C4MD00310A
Author version available: Download Author version (PDF)
Citation: Med. Chem. Commun., 2014,5, 1563-1566
  •   Request permissions

    Non-classical β-carbonic anhydrase inhibitors-towards novel anti-mycobacterials

    N. von Gnielinski, L. Nienaber, L. Mason, S. Ellis, J. A. Triccas, R. A. Davis and A. Hofmann, Med. Chem. Commun., 2014, 5, 1563
    DOI: 10.1039/C4MD00310A

Search articles by author

Spotlight

Advertisements